List of Excipients in Branded Drug ERIBULIN MESYLATE

Generic Drugs Containing ERIBULIN MESYLATE

Company	Ingredient	NDC	Excipient
HIKMA PHARMACEUTICALS USA INC	eribulin mesylate	0143-9167	ALCOHOL
HIKMA PHARMACEUTICALS USA INC	eribulin mesylate	0143-9167	HYDROCHLORIC ACID
HIKMA PHARMACEUTICALS USA INC	eribulin mesylate	0143-9167	SODIUM HYDROXIDE
HIKMA PHARMACEUTICALS USA INC	eribulin mesylate	0143-9167	WATER
Sandoz Inc	eribulin mesylate	0781-3391	ALCOHOL

What are the Most Frequently-Used Excipients in ERIBULIN MESYLATE?

# Of NDCs	Excipient
15	ALCOHOL
15	HYDROCHLORIC ACID
1	NITROGEN
15	SODIUM HYDROXIDE
15	WATER

Eribulin Mesylate Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

Eribulin mesylate is a mature oncology injectable with a simple formulation, limited excipient burden, and established generic competition. Its main commercial opportunities are not novel excipient discovery. They are supply reliability, ready-to-use presentations, reduced preparation time, container optimization, stability improvements, and regional access. The reference product, Halaven, is an intravenous solution containing eribulin mesylate, ethanol, and Water for Injection. The formulation’s simplicity lowers development risk but also limits differentiation based solely on excipients.[1]

What is the current formulation of eribulin mesylate?

Halaven is supplied as a sterile, preservative-free intravenous solution in a single-dose vial. The labeled strength is 1 mg eribulin mesylate in 2 mL, equivalent to 0.88 mg eribulin base. The product is administered after dilution in compatible intravenous fluids, according to the prescribing information.[1]

Formulation attribute	Reference-product profile
Active ingredient	Eribulin mesylate
Dosage form	Sterile intravenous solution
Strength	1 mg/2 mL
Route	Intravenous infusion
Primary container	Single-dose vial
Preservative	None stated in the U.S. label
Key excipients	Ethanol and Water for Injection
pH control	Manufacturing-process and product specifications apply
Storage	Controlled room-temperature and in-use conditions under the approved label
Main clinical use	Unresectable or metastatic breast cancer; unresectable or metastatic liposarcoma after prior anthracycline therapy

The absence of complex surfactants, lipids, polymers, or lyophilization aids reduces formulation and analytical complexity. It also means a follow-on product must compete through price, manufacturing efficiency, supply continuity, packaging, and service rather than through a materially differentiated excipient platform.

Which excipients are used in eribulin mesylate injection?

The principal excipients identified in the U.S. Halaven labeling are ethanol and Water for Injection.[1] Ethanol functions primarily as a solvent and supports solubilization of the active pharmaceutical ingredient. Water for Injection is the aqueous vehicle.

The formulation strategy has several implications:

1. It avoids high-risk excipient classes such as polysorbates, polyethylene glycol, amino acids, phospholipids, and complex buffering systems.
2. It places greater importance on ethanol concentration, container compatibility, extractables and leachables, and solution stability.
3. It creates a relatively accessible formulation target for generic manufacturers.
4. It limits the value of conventional excipient substitution because the reference formulation already has a low ingredient count.

A manufacturer developing a generic product should seek pharmaceutical equivalence with the reference product and avoid unnecessary excipient changes. Changes in ethanol content, pH, osmolality, vial closure, or dilution behavior can create comparability and regulatory issues even when the active ingredient is unchanged.

What excipient risks affect eribulin mesylate commercialization?

Ethanol compatibility

Ethanol can interact with elastomeric closures, vial coatings, syringe components, and plastic administration systems. The development program should assess:

• Sorption or permeation through container components
• Extractables from rubber closures and plastic components
• Closure integrity over the full shelf life
• Changes in appearance, particulate burden, or assay
• Compatibility with dilution bags and infusion sets
• Operator exposure during preparation

The risk is manageable, but it shifts attention from active-excipient interaction to packaging-system performance.

Solution stability

Eribulin mesylate is supplied as a solution rather than a powder for reconstitution. The formulation must maintain chemical purity, potency, clarity, and particulate control during storage and after dilution. A stability program should evaluate:

• Oxidative degradation
• Hydrolysis
• Light exposure
• Temperature excursions
• Freeze-thaw exposure
• Diluted-product hold time
• Compatibility with common infusion fluids

The prescribing information governs the approved dilution and storage conditions. A sponsor seeking broader in-use claims would need supporting stability data and regulatory approval rather than relying on general intravenous compatibility assumptions.[1]

Microbiological control

A single-dose, preservative-free vial reduces preservative-related toxicity and compatibility concerns. It also requires strict sterile manufacturing, container-closure integrity, and validated aseptic processing. A multidose presentation would introduce a different risk profile and could require antimicrobial preservatives, a new closure system, and additional clinical and regulatory justification.

What formulation opportunities exist for eribulin mesylate?

Ready-to-use or pharmacy-ready bags

A premixed infusion bag could reduce pharmacy preparation steps and limit vial manipulation. Potential advantages include:

• Lower compounding labor
• Reduced dosing and dilution errors
• Less occupational handling
• Easier adoption in outpatient oncology centers
• Better suitability for centralized pharmacy operations

The primary barriers are stability after dilution, container compatibility, shipping qualification, and the need to establish an appropriate commercial dose-volume configuration. The product would also need to address variable patient doses and waste management.

A manufacturer could pursue a limited set of standard presentations, such as a pharmacy-ready bag for common adult doses. The commercial value would be strongest in high-volume infusion centers, integrated delivery networks, and markets with centralized oncology pharmacy services.

Ready-to-administer syringe

A prefilled syringe could support low-volume administration and reduce preparation time. Its value is less clear than a premixed bag because eribulin is generally administered by infusion and oncology facilities already use controlled preparation processes. Syringe-based delivery would also create device, stability, and compatibility requirements.

This approach is more attractive for specialized hospital systems than for broad generic substitution. It may be commercially viable where labor costs and handling controls are significant.

Dual-chamber or reconstitution systems

A dual-chamber system could separate eribulin mesylate from an aqueous vehicle until use. This approach would be technically unnecessary if the solution formulation already has adequate shelf life. It would increase device complexity, manufacturing cost, and regulatory burden.

The commercial case would require a demonstrated benefit, such as materially longer shelf life, improved temperature robustness, or a simplified administration process.

Lyophilized eribulin mesylate

A lyophilized product could improve stability in some packaging configurations, but it would require bulking agents, tonicity agents, collapse-control excipients, and reconstitution studies. Typical development candidates could include mannitol, sucrose, or other approved parenteral excipients, but the choice would depend on cake structure, reconstitution time, pH, potency, and degradation pathways.

Lyophilization is unlikely to be the first-line opportunity for a generic eribulin product because the reference product is already a stable solution and the added process cost may not support a premium.

Low-volume concentrated formulation

A more concentrated solution could reduce infusion volume and packaging requirements. The development risks include local tolerability, precipitation during dilution, infusion-line compatibility, and dose-preparation error. A concentration change would require evidence that the product remains pharmaceutically equivalent or otherwise meets the applicable regulatory pathway.

What commercial opportunities exist for eribulin mesylate excipient innovation?

Opportunity	Technical difficulty	Commercial value	Main barrier
Standard generic vial	Low to moderate	High for price competition	Manufacturing scale and procurement access
Ready-to-dilute vial	Low to moderate	Moderate	Differentiation from existing products
Premixed infusion bag	Moderate	Moderate to high	Diluted stability and variable dosing
Prefilled syringe	Moderate to high	Selective	Device compatibility and limited use case
Lyophilized vial	High	Low to moderate	Added cost against a stable solution
Extended in-use stability	Moderate	Moderate	Supporting stability and regulatory data
Low-volume concentration	Moderate to high	Selective	Dosing and dilution risks
Alternative container closure	Moderate	Moderate	Extractables, leachables, and integrity
Regional contract manufacturing	Low to moderate	High in access-constrained markets	Sterile capacity and quality systems

The strongest near-term opportunity is a reliable generic vial supported by efficient sterile manufacturing. A premixed presentation is the most credible product-extension opportunity. Lyophilization and complex delivery systems are less attractive unless they solve a documented operational problem.

How does eribulin mesylate compare with competing injectable oncology products?

Eribulin mesylate has a relatively simple excipient profile compared with many oncology injectables that require surfactants, cosolvents, complex buffers, or lipid systems. Its formulation is closer to a conventional aqueous small-molecule injection than to a nanoparticle or biologic product.

Product category	Typical formulation burden	Eribulin mesylate comparison
Aqueous small-molecule oncology injection	Low to moderate	Comparable
Taxane formulation	Often high because of solubilizers	Simpler
Liposomal oncology product	High	Far simpler
Monoclonal antibody	High, with protein-stability requirements	Much simpler
Lyophilized biologic	High	Much simpler
Premixed oncology infusion	Moderate to high	Opportunity for differentiated packaging

Eribulin does not present biosimilar risk because it is a chemically defined small molecule rather than a biologic. Competitive risk comes from abbreviated new drug applications, local generic approvals, hospital tenders, and branded or authorized-generic supply arrangements.

What is the FDA regulatory status of eribulin mesylate?

The FDA approved Halaven in 2010 for metastatic breast cancer and later expanded the indication to unresectable or metastatic liposarcoma after prior anthracycline therapy.[2] The product is regulated as a small-molecule drug. Generic versions follow the ANDA pathway when they demonstrate pharmaceutical equivalence and bioequivalence or satisfy applicable product-specific requirements.

The key regulatory issues for a generic injectable include:

• Same active ingredient and dosage form
• Equivalent strength
• Sterility and endotoxin control
• Comparable container-closure system
• Assay and impurity profile
• Particulate matter
• pH and osmolality
• In-use and dilution compatibility
• Labeling consistency
• Manufacturing-process validation

Because eribulin is administered intravenously, conventional oral bioequivalence studies are not the central issue. The regulatory focus shifts toward pharmaceutical equivalence, product quality, sterile manufacturing, and comparative in-vitro performance.

What patents protect eribulin mesylate?

Eribulin was developed as a synthetic analog of halichondrin B by Eisai. The historical patent estate included patents directed to halichondrin B analogs, eribulin compounds, synthetic processes, and therapeutic uses. The principal U.S. composition and product protection has largely matured, enabling generic competition in multiple markets.

Patent analysis should separate four categories:

Patent category	Relevance to eribulin mesylate
Composition-of-matter patents	Protect eribulin or related halichondrin analog structures
Salt and solid-form patents	Could cover eribulin mesylate, crystalline forms, or isolation processes
Manufacturing patents	May cover synthetic intermediates, coupling steps, purification, or scale-up
Method-of-use patents	May cover specific cancer indications, dosing schedules, or combinations

The FDA Orange Book is the controlling source for listed U.S. patents and regulatory exclusivity associated with the reference product.[3] Public patent databases identify historical Eisai patent activity, but an investment or launch decision should rely on the current Orange Book record, issued patent status, terminal disclaimers, pediatric extensions, and any applicable litigation settlement terms.

When does eribulin mesylate lose exclusivity?

Eribulin’s original new chemical entity exclusivity expired years after the 2010 approval, and the product is now exposed to generic competition. Patent barriers depend on the specific jurisdiction, patent family, and claim type. A generic manufacturer therefore faces a country-by-country assessment rather than a single global expiry date.

For commercial planning, the relevant questions are:

• Whether a valid U.S. listed patent remains enforceable
• Whether an ANDA includes a Paragraph IV certification
• Whether the reference sponsor filed an infringement action
• Whether a 30-month stay was triggered
• Whether a settlement permits an agreed launch date
• Whether manufacturing-process patents create supply risk outside the U.S.

Are there Paragraph IV challenges and generic launch risks?

Paragraph IV challenges are the principal U.S. mechanism for contesting listed patents in an ANDA. A generic applicant may certify that a listed patent is invalid, unenforceable, or not infringed. The reference sponsor can respond with patent litigation, potentially triggering a statutory stay of FDA approval.

For eribulin mesylate, generic entry risk is commercially significant because:

• The dosage form is technically accessible.
• The active ingredient is a small molecule.
• The formulation has few excipients.
• Hospital purchasers commonly use tender and formulary pricing.
• Multiple suppliers can pressure net pricing.
• Oncology products are vulnerable to supply-driven substitution.

The largest residual risk is not necessarily the basic vial formulation. It is a manufacturing or process patent that constrains an efficient route, a solid-form claim, or a settlement-controlled launch date.

What litigation and settlement issues affect eribulin mesylate?

A complete litigation assessment must examine U.S. district court complaints, Federal Circuit decisions, FDA approval dates, and settlement agreements for each ANDA applicant. The commercial impact depends on whether a case concerns:

• Composition claims
• Salt or crystalline-form claims
• Process claims
• Method-of-use claims
• Induced infringement
• Label carve-outs
• Authorized-generic arrangements

A settlement may permit an earlier launch than the nominal patent expiry, but its terms can restrict indications, manufacturing sources, or launch timing. A label carve-out can reduce method-of-use exposure while limiting the approved generic label.

No biosimilar litigation pathway applies to eribulin. The relevant competitors are generic injectable manufacturers, contract manufacturers, and distributors with sterile oncology capacity.

How strong is the eribulin mesylate patent estate?

The estate is strongest where claims cover the active chemical entity or an indispensable manufacturing route. It is weaker as a commercial barrier where:

• The composition patent has expired.
• Multiple non-infringing synthetic routes exist.
• The formulation uses common injectable excipients.
• No meaningful delivery-system patent is required.
• Generic manufacturers can reproduce the reference product without clinical reformulation.

From an excipient perspective, the estate offers limited defensive value. Ethanol and Water for Injection are established pharmaceutical materials. A manufacturer seeking differentiation would need to create protectable value through a specific premix configuration, container system, stability profile, administration device, or manufacturing process.

What geographic opportunities exist for eribulin mesylate?

The most attractive geographic opportunities are markets with:

• High breast cancer or sarcoma treatment demand
• Limited sterile injectable competition
• Reimbursement for oncology hospital products
• Local procurement preferences
• Stable access to high-quality sterile manufacturing
• Regulatory pathways for abridged injectable applications

The United States and major European markets offer volume but face price compression and established generic competition. Emerging markets may offer better margins for reliable supply, but local registration, pharmacopoeial compliance, import controls, and tender pricing can reduce returns.

A regional strategy could combine a standard vial for broad registration with a premixed bag for high-income hospital systems. Contract manufacturing partnerships may improve market access but require rigorous control of aseptic operations, change management, and supply-chain qualification.

Key Takeaways

• Eribulin mesylate has a simple injectable formulation based primarily on ethanol and Water for Injection.
• Excipient substitution alone offers limited commercial differentiation.
• The strongest product-extension opportunity is a premixed, pharmacy-ready infusion bag.
• A standard generic vial remains the lowest-risk route to market.
• Ethanol creates meaningful container-closure and extractables-and-leachables work.
• Lyophilization and complex delivery systems are unlikely to justify their cost without a clear stability or administration benefit.
• Eribulin is a small molecule, so biosimilar risk does not apply.
• Generic and authorized-generic competition is the main commercial threat.
• Patent risk should focus on remaining listed patents, process claims, method-of-use claims, Paragraph IV litigation, and settlement-controlled entry dates.
• Geographic value depends more on sterile supply reliability and procurement access than on excipient novelty.

FAQs About Eribulin Mesylate Formulation and Commercial Strategy

Can eribulin mesylate be formulated without ethanol?

A reformulated product may be technically possible, but removing ethanol would require new solubility, stability, compatibility, and regulatory work. The reference product’s ethanol content is part of its formulation profile and should not be changed casually in a generic development program.

Is eribulin mesylate suitable for a prefilled syringe?

It may be suitable in selected settings, but the commercial case is weaker than for a premixed infusion bag. Syringe development would require device compatibility, dose flexibility, stability, extractables, and administration studies.

Does eribulin mesylate require a biosimilar application?

No. Eribulin mesylate is a chemically synthesized small molecule. Follow-on products generally use generic-drug pathways rather than the biosimilar pathway.

What is the best excipient strategy for a generic eribulin injection?

The lowest-risk strategy is to match the reference product’s qualitative excipient profile and optimize the container-closure system, sterile process, filling efficiency, and stability program.

Can a new eribulin mesylate formulation obtain patent protection?

Potentially, if it contains a novel and non-obvious formulation, container, delivery system, stability profile, or manufacturing method. A simple substitution of one conventional parenteral excipient for another is less likely to create strong enforceable protection.

References

1. U.S. Food and Drug Administration. (2024). Halaven (eribulin mesylate) injection: U.S. prescribing information. Eisai Inc.
2. U.S. Food and Drug Administration. (2010). FDA approves Halaven for advanced breast cancer.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary.
5. National Cancer Institute. (2024). Eribulin mesylate. National Institutes of Health.